GlaxoSmithKline LLC recalls Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension
FDA Class III
FDA classified this recall as Class III: the product is unlikely to cause health problems but breaks the agency's rules (a labeling mistake, for example).
- Hazard
- Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.
- Products
-
- Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension
- Company
- GlaxoSmithKline LLC
- Where it was sold
-
Nationwide within the United States
Nationwide
- Units affected
- 463 Cartons
- About this recall
- Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottle of 60 tablets, one 30-mL dosing cup and one 10-mL oral dosing syringe, Rx Only, Mfd for: ViiV Healthcare Durham, NC, 27701, By: GlaxoSmithKline Durham, NC 27701, NDC 49702-255-37